Guizhou Xinbang Pharmaceutical Co Ltd (002390) — Net Asset Quality Index
Guizhou Xinbang Pharmaceutical Co Ltd (002390) has a Net Asset Quality Index of 81.2% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥8.59 Billion minus total liabilities of CN¥1.62 Billion yields net assets of CN¥6.97 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 002390 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Guizhou Xinbang Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2006–2024)
This chart shows how Guizhou Xinbang Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 19 annual periods from 2006 to 2024. As of September 2025, the index stands at 81.2%, representing net assets of CN¥6.97 Billion against total assets of CN¥8.59 Billion CNY. See 002390 book value for net asset value and shareholders' equity analysis.
Annual Net Asset Quality Index for Guizhou Xinbang Pharmaceutical Co Ltd (2006–2024)
The table below presents the year-by-year Net Asset Quality Index for Guizhou Xinbang Pharmaceutical Co Ltd from 2006 to 2024, covering 19 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Guizhou Xinbang Pharmaceutical Co Ltd (002390) total market value.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 77.8% | CN¥7.02 Billion | CN¥9.03 Billion | CN¥2.01 Billion | ▲ +0.5 pp |
| 2023 | 77.3% | CN¥7.14 Billion | CN¥9.24 Billion | CN¥2.10 Billion | ▲ +5.1 pp |
| 2022 | 72.1% | CN¥7.07 Billion | CN¥9.79 Billion | CN¥2.73 Billion | ▲ +1.2 pp |
| 2021 | 70.9% | CN¥6.83 Billion | CN¥9.63 Billion | CN¥2.80 Billion | ▲ +17.4 pp |
| 2020 | 53.5% | CN¥5.17 Billion | CN¥9.66 Billion | CN¥4.49 Billion | ▲ +5.0 pp |
| 2019 | 48.5% | CN¥5.05 Billion | CN¥10.42 Billion | CN¥5.37 Billion | ▲ +0.8 pp |
| 2018 | 47.6% | CN¥5.17 Billion | CN¥10.85 Billion | CN¥5.69 Billion | ▼ -8.9 pp |
| 2017 | 56.5% | CN¥6.76 Billion | CN¥11.95 Billion | CN¥5.20 Billion | ▼ -3.5 pp |
| 2016 | 60.1% | CN¥6.49 Billion | CN¥10.80 Billion | CN¥4.31 Billion | ▲ +19.0 pp |
| 2015 | 41.0% | CN¥2.67 Billion | CN¥6.50 Billion | CN¥3.84 Billion | ▼ -6.0 pp |
| 2014 | 47.1% | CN¥2.46 Billion | CN¥5.22 Billion | CN¥2.77 Billion | ▼ -22.6 pp |
| 2013 | 69.7% | CN¥1.04 Billion | CN¥1.49 Billion | CN¥450.69 Million | ▼ -6.9 pp |
| 2012 | 76.6% | CN¥1.02 Billion | CN¥1.33 Billion | CN¥311.99 Million | ▼ -2.1 pp |
| 2011 | 78.8% | CN¥979.53 Million | CN¥1.24 Billion | CN¥264.02 Million | ▼ -6.5 pp |
| 2010 | 85.3% | CN¥959.70 Million | CN¥1.13 Billion | CN¥165.81 Million | ▲ +31.5 pp |
| 2009 | 53.8% | CN¥252.83 Million | CN¥470.35 Million | CN¥217.51 Million | ▲ +6.8 pp |
| 2008 | 46.9% | CN¥207.69 Million | CN¥442.73 Million | CN¥235.04 Million | ▲ +2.4 pp |
| 2007 | 44.5% | CN¥174.08 Million | CN¥391.07 Million | CN¥216.99 Million | ▲ +6.5 pp |
| 2006 | 38.0% | CN¥144.17 Million | CN¥379.34 Million | CN¥235.18 Million | — |